摘要
背景与目的:NY-ESO-1属癌症-睾丸抗原家族,能激发肿瘤患者同时产生细胞免疫和体液免疫,特异杀伤肿瘤细胞,被认为是目前免疫原性最强的肿瘤抗原。本研究旨在探讨NY-ESO-1在肝细胞癌中的表达及其与肝癌临床病理特征的关系。方法:用逆转录聚合酶链反应(RT-PCR)分析62例肝癌和相应癌旁肝组织NY-ESO-1m RNA表达;将145例肝癌石蜡组织制成芯片(132例有效),应用免疫组织化学EliVisionTM两步法观察NY-ESO-1蛋白的表达和分布。结果:NY-ESO-1基因在肝细胞癌中的阳性率是27.4%(17/62),肝癌伴门脉癌栓者达40%(10/25),高于不伴门脉癌栓的18.9%(7/37);NY-ESO-1蛋白主要分布在肝癌细胞胞浆,在肝癌组织芯片中的阳性率为18.9%(25/132),肝癌伴转移病变者为29.6%(16/54),不伴转移病变的阳性率仅11.5%(9/78),二者比较有显著性差异(P<0.05);NY-ESO-1基因和蛋白在H BsAg阳性肝癌标本中阳性率分别为28.3%(15/53)和19.1%(22/115),AFP≥20滋g/L标本的阳性率为29.5%(13/44)和20.7%(19/93),与H BsAg阴性和AFP正常的肝癌比较均无显著性差异(P>0.05);所有癌旁肝组织均未见NY-ESO-1的表达。结论:NY-ESO-特异表达于肝癌细胞,在有转移病变的病例中有较高的阳性率,提示NY-ESO-1可能与肝癌病情进展和转移有关,可作为肝癌。
BACKGROUND & OBJECTIVE: NY-ESO-1 belongs to cancer-testis antigen family. It can inspire both cellular and humoral immune responses in tumor patients, and is regarded as the strongest tumor antigen. This study was to investigate the expression of NY-ESO-1 gene and its correlation with clinicopathologic features of hepatocellular carcinoma (HCC). METHODS: NY-ESO-1 mRNA expression was detected by reverse transcription-polymerase chain reaciton (RT-PCR) in 62 specimens of HCC and adjacent liver tissue. NY-ESO-1 protein expression and its distribution were detected by immunohistochemistry (IHC) in a tissue microarray contained 132 eligible cases of HCC. RESULTS: Positive rate of NY-ESO-1 mRNA was 27.4% in HCC; it was higher in HCC with tumor embolus of portal vein than in HCC without tumor embolism (40.0% vs. 18.9%). Positive rate of NY-ESO-1 protein was 18.9% in HCC tissue microarray; it was significantly higher in HCC with metastasis than in HCC without metastasis (29.6% vs. 11.5%, P < 0.05). NY-ESO-1 protein mainly located in cytoplasm of HCC cells. Positive rates of NY-ESO-1 mRNA and protein were 28.3% and 19.1% respectively in HBsAg positive HCC, and were 29.5% and 20.7% respectively in HCC with alpha fetoprotein (AFP) of > 20ng/ml. Both NY-ESO-1 mRNA and protein were not detected in adjacent normal liver tissue. CONCLUSIONS: NY-ESO-1 gene specifically expresses in HCC, and may correlates with progress and metastasis of HCC. It may be a candidate target for antigen-specific immunotherapy for HCC with metastatic lesion. NY-ESO-1 expression has no correlation with HBsAg/AFP status of HCC.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2005年第5期622-626,共5页
Chinese Journal of Cancer
基金
广州市科技计划项目基金(No.2003J1-C0221)~~
关键词
NY—ESO-1
肝肿瘤
RT—PCR
组织芯片
临床病理特征
NY-ESO-1
Liver neoplasms
Reverse transcription-polymerase chain reaciton
Tissue microarray
Clinicopathologic features
